Comprehensive Summary
With continued technological developments in medicine, advancements in artificial intelligence (AI) have made some significant contributions to prostate cancer screening. In regards to micro-ultrasound and multimodal magnetic resonance imaging, AI has allowed for improved discrimination and specificity as well as matched sensitivity, respectively. AI has also provided an alternative for noninvasive risk stratification, specifically for liquid-biopsy programs in combination with fragmentomics where AI is used for cell-free mRNA interpretation. Within other screening departments, AI has also contributed to independent prognostic values of prostate imaging-reporting and data system (PI-RADS 3) lesions; automated cancer detection; and accelerated radiotherapy planning. Translation into clinical practice still requires rigorous validative processes, but these current advancements of AI in prostate cancer screening offer promising results for the future integration of AI in medicine.
Outcomes and Implications
The increased involvement of AI in prostate cancer screening offers promising implications of its future incorporation into clinical practice. Specifically, AI involvement has the potential to create uniformity throughout screening processes, as well as increase efficiency and accuracy of screening results. This can, in turn, improve patient diagnostic outcomes and overall patient care quality.